研究者报告与中心裁定主要不良心脏事件的比较:COMPASS 试验的二次分析
该研究为 COMPASS 试验的二次分析,纳入 27 395 例稳定动脉粥样硬化性血管病患者,随机接受双通路抑制(利伐沙班 2.5 mg 每日两次+阿司匹林 100 mg 每日一次)、利伐沙班单药(5 mg 每日两次)或阿司匹林单药(100 mg 每日一次)。中心裁定使多数终点事件数减少 10%–15%。研究者报告的主要疗效终点中,双通路抑制较阿司匹林单药显著降低(4.5% vs 5.9%;HR 0.75,95%CI 0.66–0.85;P<.001),裁定终点结果相似(4.1% vs 5.4%;HR 0.76,95%CI 0.66–0.86;P<.001)。利伐沙班单药 vs 阿司匹林单药在研究者报告中显著(5.2% vs 5.9%;HR 0.88,95%CI 0.78–0.99;P=.04),但裁定终点未达显著(4.9% vs 5.4%;HR 0.90,95%CI 0.79–1.03;P=.12)。
要点
- 双通路抑制(利伐沙班 2.5 mg 每日两次+阿司匹林 100 mg 每日一次)较阿司匹林单药降低主要终点:研究者报告 4.5% vs 5.9%(HR 0.75,95%CI 0.66–0.85;P<.001),裁定 4.1% vs 5.4%(HR 0.76,95%CI 0.66–0.86;P<.001)。
- 利伐沙班单药(5 mg 每日两次)vs 阿司匹林单药:研究者报告 5.2% vs 5.9%(HR 0.88,95%CI 0.78–0.99;P=.04),裁定 4.9% vs 5.4%(HR 0.90,95%CI 0.79–1.03;P=.12)。
- 中心裁定使多数终点事件数减少 10%–15%。
- 主要复合终点研究者报告与裁定的 κ 统计量为 0.94(95%CI 0.93–0.95)。
- 作者认为,在盲法临床试验中使用研究者报告事件可能是比裁定更高效的替代方案。
适用人群与场景
- 稳定动脉粥样硬化性血管病患者,纳入 COMPASS 试验随机分组。
- 共 27 395 例,平均(SD)年龄 68.2(7.9)岁,78.0% 为男性;双通路抑制组 9152 例,利伐沙班单药组 9117 例,阿司匹林单药组 9126 例。
处置流程与药物剂量
- 双通路抑制:利伐沙班 2.5 mg 每日两次+阿司匹林 100 mg 每日一次。
- 利伐沙班单药:5 mg 每日两次。
- 阿司匹林单药:100 mg 每日一次。
研究设计与关键结果
- 研究类型:COMPASS 试验的二次分析;COMPASS 为国际、双盲、双模拟、随机临床试验,采用 3×2 部分析因设计;数据分析时间为 2013 年 3 月至 2017 年 2 月。
- 主要疗效终点为心血管死亡、卒中或心肌梗死的复合终点。
- 中心裁定使多数终点事件数减少 10%–15%。
- 研究者报告的主要疗效终点:双通路抑制组 411 例(4.5%)vs 阿司匹林单药组 542 例(5.9%);HR 0.75(95%CI 0.66–0.85);P<.001。
- 裁定主要疗效终点:双通路抑制组 379 例(4.1%)vs 阿司匹林单药组 496 例(5.4%);HR 0.76(95%CI 0.66–0.86);P<.001。
- 缺血终点高度一致,主要复合终点的 κ 统计量为 0.94(95%CI 0.93–0.95)。
- 研究者报告事件中,利伐沙班单药组 477 例(5.2%)vs 阿司匹林单药组 542 例(5.9%);HR 0.88(95%CI 0.78–0.99);P=.04。
- 裁定事件中,利伐沙班单药组 448 例(4.9%)vs 阿司匹林单药组 496 例(5.4%);HR 0.90(95%CI 0.79–1.03);P=.12。
证据类型、等级与局限
- 证据类型:随机临床试验(COMPASS)的二次分析。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,在盲法临床试验中使用研究者报告事件可能是比中心裁定更高效的替代方案。
指南或共识出处
- COMPASS 试验(ClinicalTrials.gov 注册号 NCT01776424)。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
IMPORTANCE: In the Cardiovascular Outcomes for People Using Anticoagulation Strategies (COMPASS) trial, there was a significant reduction in the adjudicated primary outcome among patients with stable atherosclerotic vascular disease randomized to dual pathway inhibition (rivaroxaban 2.5 mg twice daily plus aspirin 100 mg daily) vs aspirin monotherapy, but not with rivaroxaban 5 mg twice daily vs aspirin monotherapy. Whether the results are similar without adjudication is unknown.
OBJECTIVE: To examine the impact of dual pathway inhibition (with rivaroxaban plus aspirin) or rivaroxaban monotherapy compared with aspirin monotherapy on investigator-reported CV events and to understand the extent of concordance between investigator-reported and centrally adjudicated clinical events.
DESIGN, SETTING, AND PARTICIPANTS: This is a secondary analysis of the COMPASS trial, an international, double-blind, double-dummy, randomized clinical trial with a 3-by-2 partial factorial design that evaluated participants with stable atherosclerotic vascular disease receiving rivaroxaban plus aspirin, rivaroxaban monotherapy, or aspirin monotherapy. End points were collected by blinded site investigators and adjudicated by a blinded clinical end point committee. Data were analyzed from March 2013 through February 2017.
INTERVENTIONS: Participants received dual inhibition pathway (2.5 mg rivaroxaban twice daily plus 100 mg aspirin once daily), rivaroxaban monotherapy (5 mg twice daily), or aspirin monotherapy (100 mg once daily).
MAIN OUTCOMES AND MEASURES: The primary efficacy outcome was a composite of cardiovascular (CV) death, stroke, or myocardial infarction (MI). Adjudicated and investigator-reported end points were compared.
RESULTS: A total of 27 395 patients (mean [SD] age, 68.2 [7.9] years; 78.0% men) were assessed, including 9152 patients randomized to dual pathway inhibition, 9117 patients randomized to rivaroxaban monotherapy, and 9126 patients randomized to aspirin monotherapy. Adjudication reduced the number of events by 10% to 15% for most end points. Among investigator-reported end points, dual pathway inhibition significantly reduced the rate of the primary efficacy outcome compared with aspirin alone (411 patients [4.5%] vs 542 patients [5.9%]; hazard ratio [HR], 0.75 [95% CI, 0.66-0.85]; P < .001), with similar reduction in adjudicated end points, (379 patients [4.1%] vs 496 patients [5.4%]; HR, 0.76 [95% CI, 0.66-0.86]; P < .001). Likewise, effects on ischemic end points were highly concordant (κ statistic = 0.94 [95% CI, 0.93-0.95] for the primary composite end point). Unlike with adjudicated outcomes, there was a significant reduction in the primary end point with rivaroxaban monotherapy vs aspirin monotherapy using investigator-reported events (477 patients [5.2%] vs 542 patients [5.9%]; HR, 0.88 [95% CI, 0.78-0.99]; P = .04) compared with adjudicated events (448 patients [4.9%] vs 496 patients [5.4%]; HR, 0.90 [95% CI, 0.79-1.03]; P = .12).
CONCLUSIONS AND RELEVANCE: This secondary analysis of the COMPASS trial found that whether assessed by blinded site investigators or adjudicators, dual pathway inhibition significantly reduced CV events among patients with stable atherosclerotic disease compared with aspirin plus placebo. These findings suggest that using investigator-reported events in blinded clinical trials may be a more efficient alternative to adjudication.
TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT01776424.
参考来源
- Gaba P, Bhatt DL, Dagenais GR, et al. Comparison of Investigator-Reported vs Centrally Adjudicated Major Adverse Cardiac Events: A Secondary Analysis of the COMPASS Trial. JAMA Netw Open. 2022. PMID: 36409491. doi:10.1001/jamanetworkopen.2022.43201
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。